Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00069329

Recruitment Status : Terminated (data submitted for Food and Drug Administration (FDA) approval)

First Posted : September 23, 2003

Results First Posted : December 1, 2016

Last Update Posted : December 1, 2016

Sponsor:

Information provided by (Responsible Party):

National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) )

Study Type:	Interventional
Study Design:	Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
Conditions:	Nervous System Malformations Arthropathy, Neurogenic Urticaria Papilledema
Intervention:	Drug: anakinra

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
NOMID	Patients who met the criteria for NOMID and treated with escalating doses of anakinra 1-5 mg/kg/day to achieve laboratory and organ inflammation remission.

Participant Flow: Overall Study

	NOMID
STARTED	43
COMPLETED	41
NOT COMPLETED	2

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
NOMID	Patients who met the criteria for NOMID and treated with escalating doses of anakinra 1-5 mg/kg/day to achieve laboratory and organ inflammation remission.

Baseline Measures

	NOMID
Overall Participants Analyzed [Units: Participants]	43

Age [Units: Participants]
<=18 years	36
Between 18 and 65 years	7
>=65 years	0

Gender [Units: Participants]
Female	25
Male	18

Ethnicity (NIH/OMB) [Units: Participants]
Hispanic or Latino	8
Not Hispanic or Latino	33
Unknown or Not Reported	2

Race (NIH/OMB) [Units: Participants]
American Indian or Alaska Native	0
Asian	4
Native Hawaiian or Other Pacific Islander	0
Black or African American	1
White	29
More than one race	1
Unknown or Not Reported	8

Outcome Measures

Show All Outcome Measures

1. Primary:

Diary Symptom Sum Score (DSSS) (Fever, Rash, Joint Pain, Vomiting, and Headaches) [ Time Frame: Baseline ]

Show Outcome Measure 1

2. Primary:

Diary Symptom Sum Score (DSSS) (Fever, Rash, Joint Pain, Vomiting, and Headaches) [ Time Frame: 36 months ]

Show Outcome Measure 2

3. Primary:

Diary Symptom Sum Score (DSSS) (Fever, Rash, Joint Pain, Vomiting, and Headaches) [ Time Frame: 60 months ]

Show Outcome Measure 3

4. Primary:

Patient / Parent Global Score of Overall Disease Activity [ Time Frame: Baseline ]

Show Outcome Measure 4

5. Primary:

Patient / Parent Global Score of Overall Disease Activity [ Time Frame: 36 months ]

Show Outcome Measure 5

6. Primary:

Patient / Parent Global Score of Overall Disease Activity [ Time Frame: 60 months ]

Show Outcome Measure 6

7. Primary:

Parent /Patient Pain Rating [ Time Frame: Baseline ]

Show Outcome Measure 7

8. Primary:

Parent /Patient Pain Rating [ Time Frame: 36 months ]

Show Outcome Measure 8

9. Primary:

Parent /Patient Pain Rating [ Time Frame: 60 months ]

Show Outcome Measure 9

10. Primary:

Childhood Health Assessment Questionnaire (CHAQ) [ Time Frame: Baseline ]

Show Outcome Measure 10

11. Primary:

Childhood Health Assessment Questionnaire (CHAQ) [ Time Frame: 36 months ]

Show Outcome Measure 11

12. Primary:

Childhood Health Assessment Questionnaire (CHAQ) [ Time Frame: 60 months ]

Show Outcome Measure 12

13. Primary:

Serum Amyloid A (SAA) Measurement [ Time Frame: Baseline ]

Show Outcome Measure 13

14. Primary:

Serum Amyloid A (SAA) Measurement [ Time Frame: 36 months ]

Show Outcome Measure 14

15. Primary:

Serum Amyloid A (SAA) Measurement [ Time Frame: 60 months ]

Show Outcome Measure 15

16. Primary:

C-reactive Protein (CRP) Measurement [ Time Frame: Baseline ]

Show Outcome Measure 16

17. Primary:

C-reactive Protein (CRP) Measurement [ Time Frame: 36 months ]

Show Outcome Measure 17

18. Primary:

C-reactive Protein (CRP) Measurement [ Time Frame: 60 months ]

Show Outcome Measure 18

19. Primary:

Erythrocyte Sedimentation Rate (ESR) Measurement [ Time Frame: Baseline ]

Show Outcome Measure 19

20. Primary:

Erythrocyte Sedimentation Rate (ESR) Measurement [ Time Frame: 36 months ]

Show Outcome Measure 20

21. Primary:

Erythrocyte Sedimentation Rate (ESR) Measurement [ Time Frame: 60 months ]

Show Outcome Measure 21

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Data reported is on 26 patients who completed their 3 year assessment and 20 of these patients also completed their 5 year assessment.

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:

Name/Title: Goldbach-Mansky, Raphaela
Organization: National Inst of Arthritis and Musculoskeletal and Skin Diseases
phone: +1 301 435 6243
e-mail: goldbacr@mail.nih.gov

Publications:

Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, Teillac-Hamel D, Fischer A, de Saint Basile G. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet. 2002 Jul;71(1):198-203. Epub 2002 May 24.

Hashkes PJ, Lovell DJ. Recognition of infantile-onset multisystem inflammatory disease as a unique entity. J Pediatr. 1997 Apr;130(4):513-5.

Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001 Nov;29(3):301-5.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rodriguez-Smith J, Lin YC, Tsai WL, Kim H, Montealegre-Sanchez G, Chapelle D, Huang Y, Sibley CH, Gadina M, Wesley R, Bielekova B, Goldbach-Mansky R. Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Blood-Brain Barrier Function in Neonatal-Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatal-Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. Arthritis Rheumatol. 2017 Jun;69(6):1325-1336. doi: 10.1002/art.40055. Epub 2017 May 10.

Kullenberg T, Löfqvist M, Leinonen M, Goldbach-Mansky R, Olivecrona H. Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes. Rheumatology (Oxford). 2016 Aug;55(8):1499-506. doi: 10.1093/rheumatology/kew208. Epub 2016 May 3.

Chang Z, Spong CY, Jesus AA, Davis MA, Plass N, Stone DL, Chapelle D, Hoffmann P, Kastner DL, Barron K, Goldbach-Mansky RT, Stratton P. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol. 2014 Nov;66(11):3227-32.

Sibley CH, Plass N, Snow J, Wiggs EA, Brewer CC, King KA, Zalewski C, Kim HJ, Bishop R, Hill S, Paul SM, Kicker P, Phillips Z, Dolan JG, Widemann B, Jayaprakash N, Pucino F, Stone DL, Chapelle D, Snyder C, Butman JA, Wesley R, Goldbach-Mansky R. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 2012 Jul;64(7):2375-86. doi: 10.1002/art.34409.

Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, Cole JL, Paul SM, Hawkins PN, Pham TH, Snyder C, Wesley RA, Hoffmann SC, Holland SM, Butman JA, Kastner DL. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006 Aug 10;355(6):581-92.

Responsible Party:	National Institutes of Health Clinical Center (CC) ( National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) )
ClinicalTrials.gov Identifier:	NCT00069329 History of Changes
Other Study ID Numbers:	030298 ZIAAR041138-08 ( U.S. NIH Grant/Contract ) 03-AR-0298 ( Other Identifier: NIHCC )
First Submitted:	September 22, 2003
First Posted:	September 23, 2003
Results First Submitted:	May 6, 2016
Results First Posted:	December 1, 2016
Last Update Posted:	December 1, 2016

To Top